Give Cas a Chance: An Actionable Path to a Platform for CRISPR Cures

Abstract

Get full access to this article

View all access options for this article.

References

US FDA. CASGEVY (Exagamglogene Autotemcel), Suspension for Intravenous Infusion. Available from: https://www.fda.gov/media/174615/download

Locatelli

, Lang

, Wall

, et al. CLIMB THAL-111 Study Group. Exagamglogene autotemcel for transfusion-dependent β-thalassemia. N Engl J Med, 2024; 390(18):1663–1676; doi: 10.1056/NEJMoa2309673

Frangoul

, Locatelli

, Sharma

, et al. CLIMB SCD-121 Study Group. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med, 2024; 390(18):1649–1662; doi: 10.1056/NEJMoa2309676

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy. Available from: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-phase-3

Gillmore

, Gane

, Taubel

, et al. CRISPR-Cas9 In Vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385(6):493–502; doi: 10.1056/NEJMoa2107454

USDA. Food Waste FAQs. Available from: https://www.usda.gov/foodwaste/faqs

USDA. Food Security in the U.S. Available from: https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-u-s/

Bousfiha

, Moundir

, Tangye

, et al. The 2022 Update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol, 2022; 42(7):1508–1520; doi: 10.1007/s10875-022-01352-z

Stitt

. 11-Year-Old Boy Receives Gene-Editing Treatment to Restore Vision. Available from: https://www.wisn.com/article/11-year-old-new-gene-editing-treatment-to-restore-vision/60769143

10.

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial. Available from: https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-clinical-data-demonstrating-proof

11.

Urnov

. Imagine CRISPR cures. Mol Ther, 2021; 29(11):3103–3106; doi: 10.1016/j.ymthe.2021.10.019

12.

Kanter

, Walters

, Krishnamurti

, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med, 2022; 386(7):617–628; doi: 10.1056/NEJMoa2117175

13.

Feuerstein

. Gene therapy for sickle cell disease remains a tough business model—and may never work. Available from: https://www.statnews.com/2024/09/26/gene-therapy-sickle-cell-bluebird-lyfgenia/

14.

Kohn

, Booth

, Shaw

, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med, 2021; 384(21):2002–2013; doi: 10.1056/NEJMoa2027675

15.

Mamcarz

, Zhou

, Lockey

, et al. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med, 2019; 380(16):1525–1534; doi: 10.1056/NEJMoa1815408

16.

Jinek

, Chylinski

, Fonfara

, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337(6096):816–821; doi: 10.1126/science.1225829

17.

FDA. Platform Technology Designation Program for Drug Development. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development

18.

Weber

, Carlino

, Khattak

, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet, 2024; 403(10427):632–644; doi: 10.1016/S0140-6736(23)02268-7

19.

Warne

, Ruesch

, Siwik

, et al. Delivering 3 billion doses of Comirnaty in 2021. Nat Biotechnol, 2023; 41(2):183–188; doi: 10.1038/s41587-022-01643-1

20.

Kim

, Hu

, Moufawad El Achkar

, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med, 2019; 381(17):1644–1652; doi: 10.1056/NEJMoa1813279

21.

England Rare Diseases Action Plan 2024: Main Report. Available from: https://www.gov.uk/government/publications/england-rare-diseases-action-plan-2024/england-rare-diseases-action-plan-2024-main-report

22.

Ecker

, Aiello

, Arron

, et al. Opportunities and challenges for innovative and equitable healthcare. Nat Rev Drug Discov, 2024; 23(5):321–322; doi: 10.1038/d41573-024-00032-4

23.

Kliegman

, Zaghlula

, Abrahamson

, et al. A roadmap for affordable genetic medicines. Nature, 2024; doi: 10.1038/s41586-024-07800-7